Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Advertisements

Management of T1 Kidney Cancer Laparoscopic Surgery

Figure 1. Age Standardized Rate of Oropharyngeal Squamous Cell Carcinoma (OPSCC) in the UK, Data courtesy of the UK HPV Prevalence Study (1)

Nat. Rev. Urol. doi: /nrurol

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 1 Cellular processes involved in cancer development

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Current treatments for PNETs

Figure 2 Representative images from a right radical

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 1 The development process of the Asian

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Drugs that target WNT signalling

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 1 The dynamic nature of resistance mechanisms can be

Can I color yellow?. Can I color yellow?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 1 Comparison of LDR‑BT, HDR‑BT, and EBRT

Nat. Rev. Urol. doi: /nrurol

Figure 2 Site of action of checkpoint inhibitors and agonists being

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer Chul Kim, MD, MPH, Chuong D. Hoang, MD,

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 The VEGF family of growth factors

Detection rate for EGFR mutations in cfDNA.

Figure 5 Design of mushroom flap for glansplasty

Clinical courses of patients.

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Target volume definitions

Figure 3 Determination of the primary site

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2017.87 Figure 1 Timeline of advances in radiotherapy for the management of RCC Figure 1 | Timeline of advances in radiotherapy for the management of RCC. Reports of SABR targeting primary RCC tumours are shown in blue, developments in radiotherapy technology are shown in grey, advances in surgery are shown in green, and discoveries in basic science are shown in purple. Future and/or ongoing studies are shown in red. CBCT, cone-beam computerized tomography; CN, cytoreductive nephrectomy; PN, partial nephrectomy; RCTs, randomized controlled trials; RN, radical nephrectomy; SABR, stereotactic ablative radiotherapy; SRS, stereotactic radiosurgery; TKI, tyrosine-kinase inhibitor. Siva, S. et al. (2017) Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach Nat. Rev. Urol. doi:10.1038/nrurol.2017.87